Clinical Results:

Intra-Articular Injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial. -Kristin Salottolo, Brian Cole, and David Bar-Or 

Incidence of total knee replacement subsequent to intra-articular injection of the anti-inflammatory compound LMWF-5A versus saline: a long-term follow-up study to a randomized controlled trial- J. Schwappach, J. Schultz, K. Salottolo, and D. Bar-or 

Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults in severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial – K. Salottolo, B. Cole and D. Bar-Or 

The anti-inflammatory effect of LMWF5A and N-acetyl kynurenine on macrophages: Involvement of aryl hydrocarbon receptor in mechanism of action – L. Rael, R. Bar-Or, K. Banton, C. Mains, M. Roshon, A. Tanner, M. Lieser, D. Acuna, D. Bar-Or 

LMWF-5A for the Treatment of Severe Osteoarthritis of the Knee: Integrated Analysis of Safety and Efficacy – B. Cole, B. McGrath, K. Salottolo, D. Bar-Or

Preliminary Trial of the Intra-Articular LMWF-5A for Osteoarthritis of the Knee – J. Schwappach, SM Dryden, KM Salottolo

A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the knee. -David Bar-Or, Kristin M. Salottolo, Holli Cherevka, Matthew J. Phillips, Brian McGrath, Nathan Wei, James L. Borders, John E. Ervin, Alan Kivitz, Mark Hermann, Tammi Shlotzhauer, Melvin Churchill, Donald Slappey, Vaughan Clift 

Incidence of total knee replacement subsequent to intra-articular injection of the anti-inflammatory compound LMWF-5A versu saline: a long-term follow up study to a randomized controlled trial. -John Schwappach, Joseph Schultz, Kristin Salottolo and David Bar-Or 

Clinical Trial Related:

Regulatory Decisions during COVID-19: Efficient Nonclinical Inhalation Toxicology for a Clinical Program – Laura Goldberg, Holli Cherevka, and Philip J. Kuehl

Minimal clinically important improvement response in patients with severe osteoarthritis of the knee: Short report from a survey of clinicians. -Kristin Salottolo, Eric Stahl

Use of Saline as a Placebo in Intra-articular Injections in Osteoarthritis: Potential Contributions to Nociceptive Pain Relief. -David Bar-Or, Leonard T. Rael and Edward N. Brody 

Comment on “clinical benefit of intra-articular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trial” -David Bar-Or, Kristin Salottolo 

Science

LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC -Gregory Thomas, Elizabeth Fredrick, Melissa Hausberg, Laura Goldberg, Marshall Hoke, Michael Roshon, Charles Mains, David Bar-Or

The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the “cytokine storm” in COVID-19 patients: a hypothesis. -Gregory Thomas, Elizabeth Fredrick, Melissa Hausberg, Laura Goldberg, Marshall Hoke, Michael Roshon, Charles Mains, David Bar-Or

The low molecular weight fraction of human serum albumin upregulates COX2, prostaglandin E2, and prostaglandin D2 under inflammatory conditions in osteoarthritic knee synovial fibroblasts. -Elizabeth D. Frederick, Melissa A. Hausburg, Gregory W. Thomas, Leonard T. Rael, Edward Brody, David Bar-Or

The low molecular weight fraction of commercial human serum albumin induces acetylation of alpha-tubulin and reduces transcytosis in retinal endothelial cells. -Gregory W. Thomas, Leonard T. Rael, Melissa Hausburg, Elizabeth D. Frederick, Edward Brody, David Bar-Or

The low molecular weight fraction of human serum albumin upregulates production of 15d-PGJ2 in Peripheral Blood Mononuclear Cells. -Gregory W. Thomas, Leoanrd T. Rael, Melissa Hausburg, Elizabeth D. Frederick, Charles W. Mains, Denetta Slone, Matthew M. Carrick, David Bar-Or 

Anti-Inflammatory Activity in the Low Molecular Weight Fraction of Commercial Human Serum Albumin (LMWF-5A). -Gregory W. Thomas, Leonard T. Rael, Charles W. Mains, Denetta Slone, Matthew M. Carrick, Raphael Bar-Or, and David Bar-Or

Low Molecular Weight Fraction of Commercial Human Serum Albumin Induces Morphologic and Transcriptional Changes of Bone Marrow-Derived Mesenchymal Stem Cells. -David Bar-Or, Gregory W. Thomas, Leonard T. Rael, Elizabeth D. Frederick, Pablo Rubinstein, Edward Brody

Inflammatory Pathways in Knee Osteoarthritis: Potential Targets for Treatment. -David Bar-Or, Leoanrd T. Rael, Gregory W. Thomas, and Edward N. Brody

Dipeptidyl peptidase IV activity in commercial solutions of human serum albumin. -David Bar-Or, Denetta S. Slone, Charles W. Mains, Leoanrd T. Rael

A Diketopiperazine Fragment of Human Serum Albumin Modulates T-Lymphocyte Cytokine Production Through Rap1. -Richard Shimonkevitz, Gregory Thomas, Denetta Sue Slone, Michael Craun, Charles Mains, and David Bar-Or

Commercial human albumin preparations for clinical use are immunosuppressive in vitro. -David Bar-Or, Gregory W. Thomas, Raphael Bar-Or, Leonard T. Rael, Kristin Scraborough, Nagaraja Rao, Richard Shimonkevitz

Ampion regulates the immune response

Ampion uses the power of the immune response and is in development to treat osteoarthritis, respiratory illness due to COVID-19, and a wide range of other debilitating and life-threatening inflammatory conditions.

Learn About Ampion